Anti-Mouse RANKL (IK22/5) In Vivo Antibody

Bulk anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5)

Product Specific Citations:

Xiong et al. A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin. Nature Communications (2022).

Product Benefits:

ichorbio's anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5) is manufactured in a cGMP compliant, ISO Quality Standard 9001:2015 facility. ichorbio's low endotoxin antibodies have half the endotoxin of comparable antibodies from Bio X Cell at less than 1.0 EU/mg. If ichorbio's low endotoxin antibodies are not low enough we also offer ultra low endotoxin antibodies which have even less endotoxin (<0.5EU/mg) at an even higher purity (98% versus 95%). ichorbio: the best antibodies for in vivo research.

Target:

RANKL

Clone:

IK22/5

Isotype:

Rat IgG2a

Other Names:

Tumor necrosis factor ligand superfamily member 11, Tnfsf11, Osteoclast differentiation factor, ODF, Osteoprotegerin ligand, OPGL, Receptor activator of nuclear factor kappa-B ligand, TNF-related activation-induced cytokine, TRANCE, CD254

Uniprot:

O35235

Host:

Rat

Species Reactivity:

Mouse

Specificity:

Anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5) recognizes an epitope on Mouse RANKL

Purification Method:

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine. RANKL is essential for osteoclast formation, activation, and survival. RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation. RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.

Immunogen:

Purified Recombinant Mouse RANKL (NSO-derived)

Concentration:

1.0 mg/ml

Formulation:

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity:

>95% by SDS-PAGE and HPLC

>98% by SDS-PAGE and HPLC

Endotoxin:

<0.5 EU/mg as determined by the LAL method

≤ 0.75 EU/mg as determined by the LAL method

Aggregation:

Aggregation level ≤ 5%

Aggregation level ≤ 1%

Storage:

This antibody is stable for at least 4 weeks when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C or -80°C. Avoid repeated freeze thaw cycles.

Applications:

Flow Cytometry, Immunoprecipitation, Western Blot, Blocking, Immunofluorescence, IHC (Frozen)

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Use:

Products are for research use only.

Isotype Control:

Rat IgG2a In Vivo Isotype Control - Low Endotoxin [1-1] (ICH2244)

Alternative Names: